De Sarro G B, Ascioti C, Froio F, Libri V, Nisticò G
Br J Pharmacol. 1987 Apr;90(4):675-85. doi: 10.1111/j.1476-5381.1987.tb11220.x.
The behavioural and electrocortical (ECoG) effects of clonidine were studied after microinjection into the third cerebral ventricle, or microinfusion into some specific areas of the rat brain rich in noradrenaline-containing cell bodies (locus coeruleus) or into areas receiving noradrenergic terminals (dorsal hippocampus, amygdaloid complex, thalamus, frontal and sensimotor cortex). The ECoG effects were continuously analysed and quantified by means of a Berg-Fourier analyser as total power and as power in preselected bands of frequency. Clonidine (9.4 to 75 nmol) given into the third cerebral ventricle produced behavioural sedation and sleep and a dose-dependent increase in ECoG total voltage power as well as in the lower frequency bands. Much lower doses were required to produce similar behavioural and ECoG spectrum power effects after either unilateral or bilateral microinfusion of clonidine into the locus coeruleus. Doses of clonidine equimolar to those given into the third cerebral ventricle, were almost ineffective in inducing behavioural and ECoG sleep after their microinfusion into the dorsal hippocampus. In addition, a dose (0.56 nmol) of clonidine which, given into the locus coeruleus, produced marked behavioural sleep and ECoG synchronization, lacked effects when given into the ventral or anterior thalamus, into the amygdaloid complex or onto the frontal and sensimotor cortex. The behavioural and ECoG spectrum power effects of clonidine given into the third cerebral ventricle or into the locus coeruleus were prevented by antagonists of alpha 2-adrenoceptors but not by alpha 1-adrenoceptor antagonists. Intraventricular microinjection, or microinfusion into the locus coeruleus, of yohimbine, a selective alpha 2-adrenoceptor antagonist, produced behavioural arousal, increase in locomotor and exploratory activity, tachypnoea and ECoG desynchronization with a significant reduction in total voltage power. Similar stimulatory effects were also observed after microinjection of phentolamine into the same sites. No significant effects on behaviour and ECoG activity were evoked after intraventricular injection or microinfusion into the locus coeruleus of prazosin or methoxamine.
将可乐定微量注射到第三脑室,或微量注入大鼠脑内富含去甲肾上腺素能细胞体的一些特定区域(蓝斑),或注入接受去甲肾上腺素能终末的区域(背侧海马、杏仁复合体、丘脑、额叶和感觉运动皮层)后,研究了可乐定对行为和皮层脑电图(ECoG)的影响。通过Berg - 傅里叶分析仪持续分析和量化ECoG效应,以总功率和预选频段的功率表示。将可乐定(9.4至75纳摩尔)注入第三脑室会产生行为镇静和睡眠,并使ECoG总电压功率以及低频段功率呈剂量依赖性增加。在将可乐定单侧或双侧微量注入蓝斑后,产生类似行为和ECoG频谱功率效应所需的剂量要低得多。与注入第三脑室的剂量等摩尔的可乐定,微量注入背侧海马后几乎无法诱导行为和ECoG睡眠。此外,一剂(0.56纳摩尔)可乐定注入蓝斑时会产生明显的行为睡眠和ECoG同步化,但注入腹侧或前丘脑、杏仁复合体或额叶和感觉运动皮层时则无此效应。注入第三脑室或蓝斑的可乐定对行为和ECoG频谱功率的影响可被α2 - 肾上腺素能受体拮抗剂阻断,但不能被α1 - 肾上腺素能受体拮抗剂阻断。选择性α2 - 肾上腺素能受体拮抗剂育亨宾经脑室微量注射或微量注入蓝斑后,会产生行为觉醒、运动和探索活动增加、呼吸急促以及ECoG去同步化,总电压功率显著降低。将酚妥拉明微量注射到相同部位后也观察到类似的刺激效应。将哌唑嗪或甲氧明经脑室注射或微量注入蓝斑后,对行为和ECoG活动未产生明显影响。